Welcome to the THRIVE Study
The THRIVE study (also known as HPS2-THRIVE) is an international clinical trial run by the University of Oxford's Clinical Trial Service Unit (CTSU). We want to find out if raising good HDL cholesterol (using a drug called ER niacin/laropiprant) will help to prevent heart attacks and stroke.
Who is taking part in THRIVE?
- THRIVE involves over 25,000 men and women
- Over 8,000 participants are from the UK
- Elsewhere, just under 11,000 participants are from China and 6,500 from Scandinavia
- There are over 240 hospitals and clinics currently involved in the study
As of July 2010 we have finished recruitment with over 25,000 people randomised into the THRIVE study. Over 8,000 of these are from the UK. We are no longer randomising participants, but follow-up visits will continue for the duration of the study.
Who is this website for?
- Participants taking part in the THRIVE study
- Participants' doctors and other healthcare professionals
For further information about the study click on the links in the menu bars above and to the left.
This website was last updated on 23rd September 2011
